ANAB
ANAPTYSBIO, INC
NASDAQ · Healthcare · Biotechnology · US
$49.24
+5.64%Year over year
Reported trailing growth
- Revenue
- +92.9%
- EBITDA
- +254.1%
- EBIT
- +255.5%
- EPS
- +249.0%
- Free cash flow
- +114.1%
- Operating cash flow
- +114.2%
Forward estimates
Based on analyst estimates
- Revenue
- -37.0%
- EBITDA
- +365.4%
- EPS
- +33.4%
Three-year CAGR
- Revenue
- +183.6%
- EBITDA
- +174.7%
- EBIT
- +141.7%
- Net income
- +90.9%
- EPS
- +91.0%
- Free cash flow
- +114.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026